Who are Uplizna's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Blincyto, UPLIZNA, MONJUVI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/inebilizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Uplizna — Competitive Intelligence Brief

Uplizna (INEBILIZUMAB) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD19-directed Cytolytic Antibody [EPC]. Area: Neuroscience.

marketed CD19-directed Cytolytic Antibody [EPC] B-lymphocyte antigen CD19 Neuroscience Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Uplizna (INEBILIZUMAB) — Viela Bio. Uplizna works by binding to CD19 on B-lymphocytes, marking them for destruction.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Uplizna TARGET	INEBILIZUMAB	Viela Bio	marketed	CD19-directed Cytolytic Antibody [EPC]	B-lymphocyte antigen CD19	2020-01-01
Blincyto	blinatumomab	Amgen	marketed	Bispecific CD19-directed CD3-directed T Cell Engager	B-lymphocyte antigen CD19	2014-01-01
UPLIZNA	INEBILIZUMAB-CDON	VIELA BIO	marketed	CD19-directed Cytolytic Antibody [EPC]	Low affinity immunoglobulin gamma Fc region receptor III-A, B-lymphocyte antigen CD19
MONJUVI	TAFASITAMAB-CXIX	MORPHOSYS US INC	marketed		B-lymphocyte antigen CD19

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD19-directed Cytolytic Antibody [EPC] class)

VIELA BIO · 1 drug in this class
Viela Bio · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Uplizna — Competitive Intelligence Brief. https://druglandscape.com/ci/inebilizumab. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab